339068-25-6

339068-25-6 structure

Name: HET-0016
Chemical Name: N'-(4-butyl-2-methylphenyl)-N-hydroxymethanimidamide
CAS Number: 339068-25-6
Molecular Formula: C₁₂H₁₈N₂O
Molecular Weight: 206.284
Catalog: Signaling Pathways Metabolic Enzyme/Protease Cytochrome P450
Create Date: 2017-08-15 10:01:01
Modify Date: 2025-08-26 17:57:35
HET0016 is a potent and selective 20-hydroxyeicosatetraenoic acid (20-HETE) synthase inhibitor, with IC50 values of 17.7 nM, 12.1 nM and 20.6 nM for recombinant CYP4A1-, CYP4A2- and CYP4A3-catalyzed 20-HETE synthesis, respectively. HET0016 also is a selective CYP450 inhibitor, which has been shown to inhibit angiogenesis and tumor growth[1][2].

Name	N'-(4-butyl-2-methylphenyl)-N-hydroxymethanimidamide
Synonyms	Methanimidamide, N'-(4-butyl-2-methylphenyl)-N-hydroxy- N'-(4-Butyl-2-methylphenyl)-N-hydroxyimidoformamide het0016 N-(4-butyl-2-methylphenyl)-N'-hydroxyiminoformamide hms1445d06

Description	HET0016 is a potent and selective 20-hydroxyeicosatetraenoic acid (20-HETE) synthase inhibitor, with IC50 values of 17.7 nM, 12.1 nM and 20.6 nM for recombinant CYP4A1-, CYP4A2- and CYP4A3-catalyzed 20-HETE synthesis, respectively. HET0016 also is a selective CYP450 inhibitor, which has been shown to inhibit angiogenesis and tumor growth[1][2].
Related Catalog	Research Areas >> Cardiovascular Disease Signaling Pathways >> Metabolic Enzyme/Protease >> Cytochrome P450
Target	17.7 nM (CYP4A1), 12.1 nM (CYP4A2), 20.6 nM (CYP4A3)[1], CYP450[2]
In Vitro	HET0016 is a selective, non-competitive and irreversible inhibitor of CYP4A [1]. HET0016 (100 μM; 24 hours, 48 hours) decreases migration and invasion of breast cancer metastatic cells [2]. Cell Proliferation Assay[2] Cell Line: MDA-MB-231 cells Concentration: 100 μM Incubation Time: 24 hours, 48 hours Result: Decreased migration and invasion of breast cancer metastatic cells
In Vivo	HET0016 (10 mg/kg/day; i.v.; for 3 weeks) reduces tumor volume and lung metastasis in an immunocompetent breast cancer mouse model[2]. HET0016 reduces the metalloproteinases’ levels in the lungs via PI3K/AKT pathway in mice[2]. HET0016 decreases expression of pro-inflammatory and growth factors and granulocytic MDSCs population in lung microenvironment[2]. HET0016 protects BBB dysfunction after I/R by regulating the expression of MMP-9 and tight junction proteins[3]. Animal Model: 4–5 weeks female Balb/c mice (16-18 g)[2] Dosage: 10 mg/kg/day Administration: Intravenously; 5 days a week; for 3 weeks; starting from day 15 of tumor implantation Result: Reduced tumor volume and lung metastasis.
References	[1]. Seki T, et al. Cytochrome P450 4A isoform inhibitory profile of N-hydroxy-N'-(4-butyl-2-methylphenyl)-formamidine (HET0016), a selective inhibitor of 20-HETE synthesis. Biol Pharm Bull. 2005 Sep;28(9):1651-4. [2]. Borin TF, et al. HET0016 decreases lung metastasis from breast cancer in immune-competent mouse model. PLoS One. 2017 Jun 13;12(6):e0178830. [3]. Liu Y, et al. The protective effect of HET0016 on brain edema and blood-brain barrier dysfunction after cerebral ischemia/reperfusion. Brain Res. 2014 Jan 28;1544:45-53.

Density	1.0±0.1 g/cm3
Boiling Point	356.9±52.0 °C at 760 mmHg
Molecular Formula	C₁₂H₁₈N₂O
Molecular Weight	206.284
Flash Point	169.7±30.7 °C
Exact Mass	206.141907
PSA	44.62000
LogP	4.13
Vapour Pressure	0.0±0.8 mmHg at 25°C
Index of Refraction	1.524

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

339068-25-6	73287-35-1
73287-36-2	66766-04-9
1221792-83-1	682802-80-8
302936-53-4	115903-57-6
78364-55-3	1150618-49-7
2167788-49-8	2166842-42-6
2167089-16-7	2166611-65-8
2167429-19-6	2166652-51-1
2168263-21-4	2167889-72-5
2229181-53-5	2228819-88-1